,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'breast', 'destinybreast04']
#asco22 #plenary3 dr. modi presents "t-dxd vs physician s choice in her2-low unresectable and/or metastatic #bcsm: #destinybreast04 mpfs: 10.1 v 5.4 m, all: 9.9 vs 5.1 mos (hr+): 23.9 vs 17.5 m, all: 23.4 vs 16.8 mpfs/os, rx duration but 12% ild 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own